Mabwell(SH:688062) Ge Long Hui A P P·2025-10-13 13:57Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911, marking a significant advancement in its drug development pipeline [1] Group 1: Drug Development - The clinical trial approval pertains to 7MW4911, which features a highly engineered design integrating three core components: a CDH17 high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] - The drug is designed to overcome multi-drug resistance mechanisms, enhancing its potential effectiveness in cancer treatment [1] Group 2: Mechanism of Action - MF-6 is noted for its excellent plasma stability, controllable drug release, and strong bystander effect, which significantly enhances its anti-tumor activity [1]